Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells

Pei‐Hua Lu(Wuxi People's Hospital), Shukui Qin(Memorial Sloan Kettering Cancer Center)
Oncotarget
February 9, 2017
10.18632/oncotarget.15205
Cited by 51

Related Papers

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
|Nature|2021|687
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
|The Lancet|2023|461
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
|˜The œLancet. Gastroenterology & hepatology|2024|245
Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis
|Scientific Reports|2016|160